Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-868-4 | CAS number: 624-89-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- The effects of a synthetic diet on the pharmacokinetics of ethyl methyl sulphide and its sulphoxide and sulphone metabolites in rats
- Author:
- Nnane IP, Damani LA and Hutt AJ
- Year:
- 2 001
- Bibliographic source:
- European Journal of Drug Metabolism and Pharmacokinetics, 26(1/2), 17-24
Materials and methods
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- - characterization of the pharmacokinetics of EMS at different doses following intravenous and oral administration,
- evaluation of modifications of the pharmacokinetics of EMS generated by placing male wistar rats on chemically defined diets?
- evaluation of metabolite pharmacoklnetics in control rats and rats maintained on the synthetic diet after administration of EMS or the S-oxygenated metabolites metabolites. - GLP compliance:
- no
Test material
- Reference substance name:
- Ethyl methyl sulphide
- EC Number:
- 210-868-4
- EC Name:
- Ethyl methyl sulphide
- Cas Number:
- 624-89-5
- Molecular formula:
- C3H8S
- IUPAC Name:
- (methylsulfanyl)ethane
- Test material form:
- other: liquid
- Details on test material:
- EMS was purchased from Aldrich chemical company (Gillingham, Dorset, UK). EMSO and EMS02 were synthesized by the laboratory using published procedures for oxidation of sulphides. The chemical purity of all compounds was greater than 98%.
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Bantin and Kingman Limited (Aldbrough, Hull, U.K.)
- Age at study initiation: no data
- Weight at study initiation: 230-280g
- Fasting period before study: no data
- Housing: no data
- Individual metabolism cages: yes/no
- Diet: normal rat chow or synthetic diet [47% dextrln (type 2), 23% sucrose, 10% corn oil, 14% amino acids and supplemented with vitamins and minerals], ad libitum
- Water (e.g. ad libitum): no data
- Acclimation period: at least 4 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20
- Humidity (%): 50
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- other: oral and iv.
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- Single administration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
EMS: 40 mg/kg (orally); 10, 20 and 40 mg/kg (intravenously)
EMSO: 5 mg/kg (intravenously)
EMSO2: 15 mg/kg (intravenously)
- No. of animals per sex per dose / concentration:
- 6
- Control animals:
- no
- Details on study design:
- The rats (n = 6) were surgically prepared under hypnorm/hypnovel anaesthesia by implanting indwelling cannula into the jugular veln and the carotid
artery, 24 h prior to drug administration and blood sampllng. EMS, EMSO or EMS02 were admlnistered as a single bolus dose through the jugular veln or orally by gavage. - Details on dosing and sampling:
- Arterial blood samples (250 ml ??) were collected in heparinized tubes pre-dose and post-dose at 5, 15, 30, 45 mins, and at 1,2, 3,4,5, 6, 7, 8 and24 h.
Blood Jevels of EMS were analysed by a sensitive headspace gas chromatographic assay. The collected blood (250 ml) was placed in 5 ml serum bottles. The internal standard, dimethyl sulphide (25 ml of 2S mg/ml), was added and this was followed by addition of potassium carbonate (0.1 g). The stoppered vials were then vortex mixed and heated at 80°C for 20- 30 mins in a water bath. An aliquot (5 ml) of the headspace generated was injected directly onto the GLC column (2 m x 0.4 cm, 4% Carbowax 20M/0.8% w/w KOH on Carbopack B).
Blood levels of the sulphoxide and sulphone were monitored by a separate gas chromatography assay. To blood samples already analysed by headspace GLC, Sodium hydroxide (50 µl, 0.1 M), the internai standard, n-propyl sul phone (10 µl,4 mg/ml), and sodium chloride (0.1 g) were added. Samples were then extracted with dichloromethane (2 x S ml). The pooled extracts were evaporated to dryness and reconstituted in 20 µl of methanol. Aliqutos (5µl) of the reconstituted extracts were injected onto the GLC column (10% Carbowax 20 M on Chromosorb W (HP), 2 m x 0.4 cm). - Statistics:
- Model independent pharmacokinetic parameters were calculated with the computer program Toplit veniion 1.0 using the standard non-compartmental equations.
One way analysis of variance ( ANOV A) was used to obtain probabllity values (p) and compare different treatment groups. A p value of less than 0.05 was considered statistically significant.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- EMS (20 mg/kg, iv) was rapidly eliminated from rat blood with a terminal half-life of 0.14 h and was not detectable 1 h after administration. EMSO was detected in rat blood between 0.083 and 5 h. The blood levels of EMSO peaked at about 1 h and then declined with a slope that was shallower than that of the parent EMS. The appearance of detectable blood levels of EMSO2 was delayed to about 0.5 h after intravenous administration of EMS. The blood levels of EMSO2 then increased reaching a peak between 6 and 7 hours after administration of EMS and persisted in the systemic circulation 24 h post-dose.
The pharmacokinetics of EMS was linear over the dose range investigated.
The absorption of EMS after oral administration was rapid and the oral bioavailability was extensive (75%). After oral administration of EMS (40 mg/kg) the maximum blood concentration (Cmax.) was attained within the first 0.083 h of blood sampling and then dec1ined monoexponentially.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Ethylmethylsulphoxide (EMSO)
Ethylmethylsulphone (EMSO2)
Applicant's summary and conclusion
- Executive summary:
Ethyl methyl sulphide (EMS), a simple dialkyl sulphide, is oxidized to the corresponding sulphoxide (EMSO) and sulphone (EMS02) derivatives both in vitro and in vivo. Two distinct enzymatic pathways appear to be involved in this sulphoxidation process; the flavin-containing monooxygenasen (FMO) is largely responsib1e for the S-oxidation of EMS to its sulphoxide while both cytochrome P-450 and FMO are involved in the further oxidation of the sulphoxide to the sulphone. The pharmacokinetics of EMS and its sulphoxide and sulphone metabolites were examined in male Wistar rats placed on normal rat chow and those placed on a synthetic diet. Blood levels of EMS were analysed by a sensitive headspace gas chromatography assay. A separate gas chromatography assay was developed to monitor the blood levels of EMSO and EMSO2.. The pharmacokinetics of EMS in control rats were linear from 10 to 40 mg/kg dose range. The blood concentration-time profile of EMS declined monoexponentially, EMS was rapidly eliminated from rat blood with a terminal half-life of 0.14h and was not detectable 1 h after administration. Following intravenous administration of EMSO (5 mg/kg), the blood concentration-time profile of EMSO declined with a terminal half -live (t1/2) of 1.46 h, about ten times longer than that of the parent sulphide. After administration of EMSO2 (15 mg/kg), the sulphone was metabolically stable and was eliminated very slowly from the blood. The in vivo disposition of EMS and EMSO were clearly altered in rats maintained on a synthetic diet following administration of EMS or EMSO. The pharmacokinetic data were consistent with a diminished drug oxidising capacity in rats placed on the synthetic diet and could serve as a useful probe for monitoring the regulation of FMO in animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.